摘要
目的 为临床安全应用前列地尔提供参考。方法 采用计算机检索中国知网、中国生物医学文摘数据库、万方和维普数据库中有关前列地尔致药品不良反应(ADR)的案例报道,检索时限为1993年1月至2023年10月,从患者性别、年龄、临床诊断、药物过敏史、用法用量、溶剂、联合用药及ADR累及系统/器官、临床表现、发生与持续时间、处置措施、预后等进行统计和分析。结果 共获得文献28篇,涉及36例患者,男女比为1.57∶1,好发于50岁及以上人群(69.44%),用法用量主要为静脉滴注(77.78%),剂量主要为每次10~20μg(77.78%),溶剂主要为0.9%氯化钠注射液(77.78%),联合用药27例(75.00%)。ADR多发生于用药后0.5 h内(61.11%),持续时间多短于1 h(50.00%),累及系统/器官以循环系统为主(47.89%),临床表现主要为静脉炎(9.86%),可通过硫酸镁湿敷缓解,也可发生过敏性休克,一旦发生需立即采取相关急救措施进行抢救。结论 临床使用前列地尔时应了解其ADR的发生规律和特点,减少ADR的发生。若发生ADR应及时采取合理的处置措施,保障患者安全用药。
Objective To provide a reference for the safe clinical application of alprostadil.Methods The case reports of adverse drug reactions(ADRs) caused by alprostadil in the CNKI,CBMdisc,WanFang and VIP databases were searched from January 1993to October 2023.The patient′s gender,age,clinical diagnosis,history of drug allergies,usage and dosage,solvents,combination therapy,ADR,involved systems/organs,clinical manifestation,occurrence and duration time,intervention measures,and prognosis were statistically analyzed.Results A total of 28 articles were obtained,involving 36 patients.The male-to-female ratio was 1.57∶1,and it was more common in people over 50 years old(69.44%).The main dosage is intravenous infusion(77.78%),with a dose of 10-20 μg per time(77.78%).The main solvent was 0.9% Sodium Chloride Injection(77.78%),and 27 cases(75.00%)were treated with combination therapy.ADRs were more common within 0.5 h after medication(61.11%) and lasted for less than1 h(50.00%).The mainly involved systems/organs was circulatory system(47.89%).The clinical manifestation was mainly phlebitis(9.86%),which could be relieved by magnesium sulfate wet compress.Allergic shock might also occur,and once it occurred,relevant emergency measures should be taken immediately for rescue.Conclusion The occurrence pattern and characteristics of ADRs caused by alprostadil in the clinic should be understood,in order to reduce the occurrence of ADRs.If ADR occurs,reasonable measures should be taken immediately to ensure the patients′ medication safety.
作者
赵志敏
何小倩
叶振昊
王静
黄超原
ZHAO Zhimin;HE Xiaoqian;YE Zhenhao;WANG Jing;HUANG Chaoyuan(The First Clinical College of Guangzhou University of Chinese Medicine,Guangzhou,Guangdong,China 510405;The Second Clinical College of Guangzhou University of Chinese Medicine,Guangzhou,Guangdong,China 510405;The Second Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou,Guangdong,China 510120;Guangdong Provincial Hospital of Chinese Medicine,Guangzhou,Guangdong,China 510120)
出处
《中国药业》
CAS
2024年第21期125-128,共4页
China Pharmaceuticals
关键词
前列地尔
药品不良反应
处置措施
文献分析
alprostadil
adverse drug reactions
intervention measures
literature review
